Table 3.

Enrichment of proinflammatory responses in the mesenchymal glioblastoma subset

Number of cases; % of cases with mRNA overexpression
ProneuralMesenchymalClassicalNeural
Immune effector/genePMID referencen = 141n = 160n = 147n = 96
Proinflammatory cytokinesIFN-γ/IFNG2170545517; 1227; 1717; 1212; 13
IL-1/IL-1A1759659411; 835; 226; 417; 18
IL-2/IL-22022789014; 1014; 912; 811; 11
IL-4/IL-41738901116; 1129; 1819; 1316: 17
IL-7/IL-784730515; 435; 2220; 1415; 16
IL-12/IL-12A2251518110; 713; 835; 2412; 13
IL-15/IL-15220329847; 542; 264; 317; 18
TNF-α/TNF2207537919; 1321; 135; 313; 14
T-cell effector markersCD3/CD3D230091448; 640; 253; 29; 9
CD8/CD8A1869803412; 929; 1812; 89; 9
CD8/CD8B186980343; 322; 149; 66; 6
CD80/CD80227986839; 636; 238; 513; 14
CD86/CD86203805734; 353; 332; 119; 20
CD40/CD40229033467; 338; 246; 410; 10
MHC/HLA-A2310807812; 921; 1325; 1710; 10
MHC/HLA-B224269595; 428; 1830; 209; 9
MHC/HLA-C1705467410; 727; 1725; 1712; 13
MHC/HLA-DRA156883985; 442; 269; 611; 11
MHC/HLA-DQA11701682113; 946; 2917; 1215; 16
MHC/HLA-DPB1217163145; 445; 2810; 178; 8
β2-Microglobulin/B2M223538048; 623; 1421; 148; 8
Immune effector signaling pathwaysNF-κB/RELA1672405410; 717; 1117; 123; 3
STAT1/STAT12280531011; 820; 1330; 2010; 10
IRAK/IRAK1172650490000
STAT4/STAT4221211029; 628; 185; 315; 16
T-bet/TBX212218689612; 920; 1317; 126; 6
DNAM-1/CD226160150418; 642; 264; 311; 11
IRF7/IRF7222952388; 624; 1516; 1117; 18
Markers of innate immunityNKp46/NCR12230831114; 1022; 1422; 157; 7
NKG2D/KLRK12253056942; 3012; 86; 42; 2
NKp30/NCR32187711918; 1324; 1515; 1011; 11
NKp44/NCR21572847212; 916; 1018; 128; 8
KLRD1/KLRD11580529516; 1127; 1711; 716; 17
NK/CD244196384678; 642; 264; 311; 11
TLR2/TLR2233243441; 156; 353; 213; 14
TLR3/TLR3231974957; 534; 2116; 1122; 23
TLR4/TLR42112917017; 1226; 168; 517; 18
TLR9/TLR92216959813; 923; 1423; 166; 6
Myeloid markersTREM1/TREM12271906612; 963; 399; 62; 2
TREM2/TREM24; 327; 176; 431; 32
MIF/MIF2177388513; 925; 168; 514; 15

NOTE: Red denotes preferential statistically significant enrichment (P < 0.05) of mRNA expression in the comparison of the mesenchymal vs. proneural subset.